DexCom selloff a buying opportunity, says Piper Sandler

Piper Sandler analyst Matt O’Brien views the post-earnings selloff in shares of DexCom as a buying opportunity. While the domestic number beat, when adjusting for the Bridge Program it came in a bit softer than investors might have expected, the analyst tells investors in a research note. DexCom’s international franchise continues to exceed expectations, and the category is "primed for excellent growth over a multi-year period," says Piper. It continues to view DexCom as its top large cap name and reiterates an Overweight rating on the shares with a $150 price target.